FDA Approves New Interchangeable Biosimilar to Pertuzumab By Ogkologos - December 3, 2025 412 0 Facebook Twitter Google+ Pinterest WhatsApp Approval is based on comparisons across a broad range of structural and functional product quality attributes Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Safety, Tolerability and Antitumour Activity of Lorlatinib in Patients with ALK-Driven... April 7, 2023 EMA Recommends Extending Indications for Pembrolizumab to Patients with Advanced Biliary... December 1, 2023 EMA Recommends Refusal of the Marketing Authorisation for Tagraxofusp August 13, 2020 Efficacy and Safety of Patritumab Deruxtecan in EGFR-mutated NSCLC Resistant to... June 16, 2021 Load more HOT NEWS Triple negative breast cancer drug given initial ‘no’ for NHS in... Cancer in My Community: Providing Supportive Care in Serbia ¿Pueden confundirse los síntomas del cáncer con la menopausia? Diagnosed 3 Weeks Before Her Wedding, She Finally Gets To Ring...
